GTS Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GTS Securities’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.4M	Sell	21,482 -3,638	-14%	-$492K	0.07%	165
2026 Q1	$3.21M	Sell	25,120 -67,958	-73%	-$8.48M	0.11%	122
2025 Q4	$11.3M	Buy	93,078 +81,119	+678%	+$9.3M	0.39%	30
2025 Q3	$1.2M	Sell	11,959 -120,861	-91%	-$10.9M	0.05%	342
2025 Q2	$11M	Buy	132,820 +52,344	+65%	+$4.18M	0.49%	31
2025 Q1	$6.53M	Buy	80,476 +11,544	+17%	+$1.03M	0.28%	43
2024 Q4	$6.21M	Sell	68,932 -27,713	-29%	-$2.68M	0.3%	48
2024 Q3	$9.55M	Buy	96,645 +78,977	+447%	+$7.76M	0.02%	534
2024 Q2	$1.64M	Buy	17,668 +878	+5%	+$78.7K	﹤0.01%	1669
2024 Q1	$1.59M	Buy	16,790 +13,652	+435%	+$1.27M	﹤0.01%	1636
2023 Q4	$280K	Sell	3,138 -77,576	-96%	-$5.76M	﹤0.01%	3272
2023 Q3	$5.89M	Buy	+80,714	New	+$6.45M	0.01%	845

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

GTS Securities's XBI Position: Q2 2026 in Review

GTS Securities reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q2 2026, selling an estimated $492K and leaving 21,482 shares worth $3.4M. The position accounts for 0.07% of the portfolio, ranked #165.

GTS Securities first reported a position in XBI in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.3M in Q4 2025. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

GTS Securities held 21,482 shares of State Street SPDR S&P Biotech ETF worth $3.4M as of Q2 2026.
GTS Securities sold 3,638 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $492K.
State Street SPDR S&P Biotech ETF made up 0.07% of GTS Securities's portfolio in Q2 2026, its #165 holding.
GTS Securities first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and has held it in 12 quarters since.
GTS Securities's State Street SPDR S&P Biotech ETF position peaked at $11.3M in Q4 2025.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.